Transcode Change In Cash from 2010 to 2024

RNAZ Stock  USD 0.34  0.04  10.53%   
Transcode Therapeutics Change In Cash yearly trend continues to be fairly stable with very little volatility. Change In Cash is likely to outpace its year average in 2024. During the period from 2010 to 2024, Transcode Therapeutics Change In Cash regression line of annual values had r-squared of  0.01 and arithmetic mean of  158,638. View All Fundamentals
 
Change In Cash  
First Reported
2019-12-31
Previous Quarter
-1.6 M
Current Value
-1.5 M
Quarterly Volatility
5.8 M
 
Covid
Check Transcode Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transcode Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 48.1 K, Tax Provision of 0.0 or Net Interest Income of 15.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.75. Transcode financial statements analysis is a perfect complement when working with Transcode Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Transcode Therapeutics Correlation against competitors.
For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Latest Transcode Therapeutics' Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Transcode Therapeutics over the last few years. It is Transcode Therapeutics' Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Transcode Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Very volatile
   Change In Cash   
       Timeline  

Transcode Change In Cash Regression Statistics

Arithmetic Mean158,638
Geometric Mean453,011
Coefficient Of Variation4,331
Mean Deviation2,772,280
Median212,859
Standard Deviation6,871,298
Sample Variance47.2T
Range35.9M
R-Value(0.07)
Mean Square Error50.6T
R-Squared0.01
Significance0.80
Slope(110,821)
Total Sum of Squares661T

Transcode Change In Cash History

2024-2.1 M
2023-2.2 M
2022-15.9 M
202120 M
2020623.5 K
2019 -8508.0

About Transcode Therapeutics Financial Statements

Transcode Therapeutics investors use historical fundamental indicators, such as Transcode Therapeutics' Change In Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Transcode Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change In Cash-2.2 M-2.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.